Announcement on Holding Subsidiary's Passing EU GMP Compliance Inspection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Holding Subsidiary's Passing EU GMP Compliance Inspection
Filed with SSE · · 2 pages · Chinese
Release
Humanwell Healthcare (Group) Co.,Ltd. on 6ix
Earlier from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Micafungin Sodium for Injection Obtaining US FDA Approval
- Announcement on the Temporary Suspension of the Shareholders’ Meeting to Deliberate on the Issuance of A-shares to Specific Investors in 2026
- Announcement on Progress in the Establishment of Private Equity Fund Investment and Related Party Transaction
- Announcement on HW221043 Tablets Obtaining Notice of Approval for Drug Clinical Trials
- Announcement on Receiving the Decision for Administrative Penalty from Hubei Securities Regulatory Bureau of China Securities Regulatory Commission
Later from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Initiation of Phase II Clinical Trial for HW091077 Tablets
- Announcement on Risk Assessment Report for China Merchants Group Finance Co., Ltd.
- Announcement on Obtaining Drug Registration Certificate by Subsidiary
- Announcement on Convening the 2025 Annual Performance Briefing
- Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Remifentanil Hydrochloride for Injection
Follow Humanwell Healthcare (Group) Co.,Ltd into a list and get an email when it puts out news.
Follow Humanwell Healthcare (Group) Co.,Ltd